LAT and non-small cell lung carcinoma: Another ongoing study that will help to clarify the role of LAT in EGFR-mutant NSCLC is the NORTHSTAR trial (NCT03410043) which randomizes patients to osimertinib with or without LAT (radiation or surgery) for Stage IIIB and Stage IV NSCLC (see Table 2).